Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 3/20 | 0.38 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.38 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.38 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.38 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.38 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.38 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.38 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.38 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1769844 | 0.74 | CYP11B2 (0.64) | CYP11B1CYP11B2SLC22A12 | |
| SCHEMBL1769940 | 0.74 | SLC22A12 (0.49) | RPS6KA3CYP11B2SLC22A12NISCH | |
| SCHEMBL6649714 | 0.73 | CYP19A1 (0.43) | NPC1RAB9A | |
| SCHEMBL6921694 | 0.72 | SLC22A12 (0.50) | RPS6KA3CYP11B1CYP11B2SLC22A12 | |
| SCHEMBL6922179 | 0.71 | CCNC (0.50) | RPS6KA3CYP11B1CYP11B2SLC22A12 | |
| SCHEMBL1769970 | 0.71 | RPS6KA3 (0.46) | RPS6KA3CYP11B1CYP11B2NPC1RAB9A | |
| SCHEMBL14225109 | 0.70 | RPS6KA3 (0.52) | RPS6KA3CYP11B1CYP11B2SLC22A12GSK3B | |
| SCHEMBL1769848 | 0.70 | SLC22A12 (0.49) | RPS6KA3CYP11B2AHRNPY5RSLC22A12 | |
| SCHEMBL8111753 | 0.69 | KIF11 (0.56) | NPY5RABL1NISCH | |
| SCHEMBL6921683 | 0.69 | RPS6KA3 (0.51) | RPS6KA3CYP11B1CYP11B2SLC22A12NISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2501678-B1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | claimed |
| CN-102712589-B | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG | 2015-05-13 | — | — | CN | claimed |
| EP-2993169-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | Novartis AG (CH) | 2016-03-09 | — | — | EP | disclosed |
| EP-2501678-B1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| EP-2501678-B1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| CN-102712589-B | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG | 2015-05-13 | — | — | CN | disclosed |
| US-8519134-B2 | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-08-27 | — | — | US | disclosed |
| US-8519134-B2 | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-08-27 | — | — | US | disclosed |
| US-8519134-B2 | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-08-27 | — | — | US | disclosed |
| US-20120316195-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120316195-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120316195-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-13 | — | — | US | disclosed |
| CN-102712589-A | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG | 2012-10-03 | — | — | CN | disclosed |
| EP-2501678-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | Novartis AG (CH) | 2012-09-26 | — | — | EP | disclosed |
| WO-2011061168-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011061168-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316195-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | RPS6KA3 1352/4885CYP11B1 2/4885CYP11B2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.